SNCA and Parkinson disease: Targeting the phosphorylation process represents a promising therapeutic approach for mitigating alpha-synuclein aggregation and regulating kinase activation involved in PD pathology (Chakraborty et al. 2017; Mahul-Mellier et al. 2014).